Cart
sales@molnova.com
Burosumab
CAS No. 1610833-03-8
Burosumab( —— )
Catalog No. M36902 CAS No. 1610833-03-8
Burosumab(KRN23) is a human monoclonal antibody targeting fibroblast growth factor 23 (FGF23) for the treatment of cutaneous-skeletal hypophosphatemic syndrome (CSHS) and tumor-induced osteochondrosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 324 | Get Quote |
|
| 5MG | 472 | Get Quote |
|
| 10MG | 757 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBurosumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionBurosumab(KRN23) is a human monoclonal antibody targeting fibroblast growth factor 23 (FGF23) for the treatment of cutaneous-skeletal hypophosphatemic syndrome (CSHS) and tumor-induced osteochondrosis.
-
DescriptionBurosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1610833-03-8
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Schindeler A, et al. Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children. Front Endocrinol (Lausanne). 2020 May 28;11:338.?
molnova catalog
related products
-
PJ34
PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.
-
Diazinon
Diazinon is a thiophosphoric acid ester is a nonsystemic organophosphate insecticide used to control cockroaches silverfish ants and fleas.
-
Cannabidivarin
Cannabidivarin is a potent inhibitor against gamma 2 subunit of GABAA receptors. it may serve as a novel drug with definite control over childhood absence epilepsy.
